INTRODUCTION {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, as the 5-year survival rate after diagnosis is only 5% \[[@R1], [@R2]\]. PDAC cells are extremely aggressive, and more than 50% of patients develop local recurrence or distant metastasis after curative resection \[[@R3], [@R4]\]. Recently developed molecularly targeted therapeutics have not shown beneficial effects in patients with PDAC \[[@R5], [@R6]\]. The molecular pathogenesis of the aggressive phenotype in PDAC remains unclear. Therefore, in order to improve disease outcomes in PDAC patients, it is necessary to define the molecular pathogenesis underlying the aggressiveness of PDAC using advanced genomic approaches.

microRNAs (miRNAs) belong to a family of short, non-coding RNAs transcribed from the human genome. Their discovery suggested new directions for the study of human cancer pathogenesis \[[@R7]\]. A unique characteristic of miRNAs is the ability of a single miRNA to tune a large number of RNA transcripts in human cells \[[@R8]\]. Thus, dysregulated miRNA expression can disrupt tightly controlled RNA networks and increase the aggressiveness of cancer cells. Numerous studies have indicated that miRNAs are aberrantly expressed in several cancers, including PDAC \[[@R9]--[@R12]\].

We have been identified anti-tumour miRNAs and their mediated novel cancer networks based on the miRNA expression signatures in various cancers \[[@R13]--[@R20]\]. Construction of miRNA signatures using clinical specimens is a first step towards identification of dysregulated miRNAs and their resultant clinical characteristics. Current RNA sequencing methods offer superior analytical approaches for studying the transcriptome. We recently showed that the passenger strand of *miR-145-3p* acted as an anti-tumour miRNA through regulating of several oncogenic genes in bladder cancer and lung cancer \[[@R21], [@R22]\]. Moreover, we showed that both strands of *pre*-*miR-139* (*miR-139-5p* and *miR-139-3p*) targeted matrix metalloprotease 11 in bladder cancer \[[@R23]\]. The involvement of passenger strand miRNAs in the regulation of cellular processes is a novel concept in RNA research.

In this study, we analysed the miRNA expression signature of PDAC clinical specimens by RNA sequencing. Using the PDAC signature, we focused on 4 clustered miRNAs, *miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p* and *miR-216b-3p* on human chromosome 2p16.1 and investigated their functional significance in PDAC pathogenesis. Transcription of all members of the *miR-216* cluster was significantly reduced in PDAC specimens, and ectopic expression of these miRNAs suppressed cancer cell aggressiveness. We further investigated the target genes of *miR-216*. The resultant data provide novel insights into the molecular pathogenesis of PDAC.

RESULTS {#s2}
=======

Construction of expression signature and identification of downregulated miRNAs in PDAC {#s2_1}
---------------------------------------------------------------------------------------

Libraries of small RNAs (from seven PDAC tissues and four normal pancreatic tissues) were analysed by using RNA sequencing technology. The patients' characteristics are shown in Table [1](#T1){ref-type="table"}. Initially, 16,930,437 to 24,733,299 raw sequence reads were produced for the libraries. After filtering for low quality and adaptors sequence reads, from 10,615,842 to 23,407,926 clean small RNA reads were obtained (Table [2](#T2){ref-type="table"}). Differentially expressed miRNAs by RNA sequence were summarized in [Supplementary Tables 1 and 2](#SD2){ref-type="supplementary-material"}.

###### Clinical features of PDAC patients

  No.       Age   Sex   T    N   M   Stage   Recurrence   Remarks
  --------- ----- ----- ---- --- --- ------- ------------ -----------------
  T1        44    M     3    1   0   IIB     (+)          deep sequencing
  T2        76    M     4    1   0   III     (+)          deep sequencing
  T3        67    M     3    1   0   IIB     (+)          deep sequencing
  T4        65    M     3    1   0   IIB     (+)          deep sequencing
  T5        56    F     3    1   1   IV      (+)          deep sequencing
  T6        83    F     3    0   0   IIA     (-)          deep sequencing
  T7        66    F     3    1   0   IIB     (-)          deep sequencing
  N1        77    F                                       deep sequencing
  N2        65    F                                       deep sequencing
  N3        71    F                                       deep sequencing
  N4        83    F                                       deep sequencing
  PCR_T1    67    M     3    1   0   IIB     (+)          RT-PCR
  PCR_T2    78    F     3    0   0   IIA     (-)          RT-PCR
  PCR_T3    58    F     3    0   0   IIA     (+)          RT-PCR
  PCR_T4    42    F     3    1   0   IIB     (+)          RT-PCR
  PCR_T5    56    F     3    0   0   IIA     (+)          RT-PCR
  PCR_T6    79    F     3    0   0   IIA     (+)          RT-PCR
  PCR_T7    63    F     3    0   0   IIA     (+)          RT-PCR
  PCR_T8    52    M     3    0   0   IIA     (-)          RT-PCR
  PCR_T9    78    F     3    1   0   IIB     (+)          RT-PCR
  PCR_T10   66    F     3    1   0   IIB     (-)          RT-PCR
  PCR_T11   66    F     3    0   0   IIA     (-)          RT-PCR
  PCR_T12   67    M     is   0   0   0       (+)          RT-PCR
  PCR_T13   74    M     4    0   0   III     (-)          RT-PCR
  PCR_T14   74    F     3    1   0   IIB     (-)          RT-PCR
  PCR_T15   65    F     3    1   0   IIB     (-)          RT-PCR
  PCR_T16   78    F     3    0   0   IIA     (-)          RT-PCR
  PCR_T17   42    M     4    1   0   III     (+)          RT-PCR
  PCR_T18   44    M     3    1   0   IIB     (+)          RT-PCR
  PCR_T19   76    M     3    1   0   IIB     (+)          RT-PCR
  PCR_T20   70    M     3    0   0   IIA     (+)          RT-PCR
  PCR_T21   78    F     1    0   0   I       (-)          RT-PCR
  PCR_T22   56    M     1    0   0   I       (+)          RT-PCR
  PCR_T23   65    M     3    0   0   IIA     (-)          RT-PCR
  PCR_T24   70    F     3    1   0   IIB     (+)          RT-PCR
  PCR_N1    76    M                                       RT-PCR
  PCR_N2    58    F                                       RT-PCR
  PCR_N3    67    M                                       RT-PCR
  PCR_N4    67    M                                       RT-PCR
  PCR_N5    42    F                                       RT-PCR
  PCR_N6    71    F                                       RT-PCR
  PCR_N7    60    M                                       RT-PCR
  PCR_N8    56    F                                       RT-PCR
  PCR_N9    67    M                                       RT-PCR
  PCR_N10   85    F                                       RT-PCR
  PCR_N11   66    F                                       RT-PCR
  PCR_N12   66    F                                       RT-PCR
  PCR_N13   44    M                                       RT-PCR
  PCR_N14   63    F                                       RT-PCR
  IHC_1     72    M     3    1   0   IIB     (+)          IHC
  IHC_2     80    M     3    1   0   IIB     (-)          IHC
  IHC_3     75    F     3    1   0   IIB     (-)          IHC
  IHC_4     60    M     4    0   0   III     (+)          IHC
  IHC_5     52    M     3    0   0   IIA     (+)          IHC
  IHC_6     50    M     4    0   0   III     (+)          IHC
  IHC_7     68    F     4    0   0   III     (-)          IHC
  IHC_8     77    F     4    0   0   III     (+)          IHC
  IHC_9     57    M     3    1   0   IIB     (+)          IHC
  IHC_10    44    M     3    1   0   IIB     (+)          IHC
  IHC_11    68    M     4    1   0   III     (+)          IHC
  IHC_12    76    M     4    1   0   III     (+)          IHC
  IHC_13    54    M     3    1   0   IIB     (+)          IHC
  IHC_14    74    F     3    1   0   IIB     (+)          IHC
  IHC_15    67    M     3    1   0   IIB     (+)          IHC
  IHC_16    76    F     3    0   0   IIA     (-)          IHC
  IHC_17    54    M     3    1   0   IIB     (+)          IHC
  IHC_18    75    F     3    0   0   IIA     (-)          IHC
  IHC_19    77    F     2    0   0   IB      (-)          IHC
  IHC_20    66    M     3    1   0   IIB     (+)          IHC
  IHC_21    69    M     3    1   0   IIB     (+)          IHC
  IHC_22    69    M     2    0   0   IB      (+)          IHC
  IHC_23    50    F     3    1   0   IIB     (+)          IHC
  IHC_24    67    F     3    1   0   III     (+)          IHC
  IHC_25    78    M     3    1   0   IIB     (+)          IHC
  IHC_26    70    M     3    1   0   IIB     (+)          IHC
  IHC_27    59    M     3    0   0   IIA     (-)          IHC
  IHC_28    74    F     3    1   0   IIB     (+)          IHC
  IHC_29    75    M     3    0   0   IIA     (+)          IHC
  IHC_30    58    F     3    0   0   IIA     (+)          IHC
  IHC_31    74    M     3    1   0   IIB     (+)          IHC
  IHC_32    59    F     3    1   0   IIB     (+)          IHC
  IHC_33    69    F     3    0   0   IIA     (-)          IHC
  IHC_34    65    F     4    1   0   III     (+)          IHC
  IHC_35    85    F     3    1   0   IIB     (+)          IHC

###### Annotation of reads aligned to small RNAs

  PDAC samples     \#T1       \#T2    \#T3       \#T4    \#T5       \#T6    \#T7                                                                
  ---------------- ---------- ------- ---------- ------- ---------- ------- ---------- ------- ---------- ------- ---------- ------- ---------- -------
  Total            17591803   100     15426965   100     16586380   100     10615842   100     18965893   100     23407926   100     12845961   100
  exon             1018127    5.79    809048     5.24    184851     1.11    155240     1.46    540260     2.85    459079     1.96    263018     2.05
  exon_antisense   9          0.00    4          0.00    5          0.00    6          0.00    3          0.00    4          0.00    10         0.00
  miRNA            3045486    17.31   4835786    31.35   3464002    20.88   1721101    16.21   2740681    14.45   2664925    11.38   3152583    24.54
  rRNA             489091     2.78    1588798    10.30   216971     1.31    440961     4.15    181910     0.96    583477     2.49    490623     3.82
  tRNA             829391     4.71    110334     0.72    1076000    6.49    141156     1.33    1067387    5.63    542804     2.32    263598     2.05
  snRNA            24109      0.14    31039      0.20    9153       0.06    14372      0.14    18154      0.10    28997      0.12    24883      0.19
  snoRNA           848025     4.82    478768     3.10    617055     3.72    260963     2.46    440008     2.32    1211925    5.18    691475     5.38
  lcnRNA           77         0.00    56         0.00    30         0.00    24         0.00    273        0.00    78         0.00    85         0.00
  ribozyme         18531      0.11    8449       0.05    7111       0.04    6490       0.06    7255       0.04    16746      0.07    10127      0.08
  sRNA             15         0.00    17         0.00    17         0.00    17         0.00    29         0.00    27         0.00    28         0.00
  Unannotated      1489059    8.46    2684735    17.40   717881     4.33    5430607    51.16   2993173    15.78   8071185    34.48   4184768    32.58
  Unmapped         9829883    55.88   4879931    31.63   10293304   62.06   2444905    23.03   10976760   57.88   9828679    41.99   3764763    29.31

  Normal pancreas samples   \#N1       \#N2    \#N3       \#N4                                  
  ------------------------- ---------- ------- ---------- ------- ---------- ------- ---------- -------
  Total                     16535900   100     20967863   100     17370365   100     18447846   100
  Exon                      281915     1.70    270434     1.29    576712     3.32    963571     5.22
  exon_antisense            2          0.00    9          0.00    39         0.00    24         0.00
  miRNA                     4247206    25.68   4331251    20.66   3534149    20.35   5133067    27.82
  rRNA                      659176     3.99    310278     1.48    1457154    8.39    810443     4.39
  tRNA                      334461     2.02    1145451    5.46    418994     2.41    568066     3.08
  snRNA                     19163      0.12    22558      0.11    28997      0.17    25124      0.14
  snoRNA                    703693     4.26    880199     4.20    714087     4.11    641479     3.48
  lcnRNA                    41         0.00    39         0.00    15         0.00    72         0.00
  ribozyme                  3967       0.02    7398       0.04    11294      0.07    9258       0.05
  sRNA                      23         0.00    31         0.00    37         0.00    32         0.00
  Unannotated               5295677    32.03   966037     4.61    2152804    12.39   1710926    9.27
  Unmapped                  4990576    30.18   13034178   62.16   8476083    48.80   8585784    46.54

We focused on 23 downregulated miRNAs (Table [3](#T3){ref-type="table"}), and these miRNAs were mapped on the human genome. We found that *miR-217, miR-216a-5p/-3p* and *miR216b-5p/-3p* were close together and were defined as clustered miRNAs. Because the role of the *miR-216* cluster had not been reported in PDAC, we focused on it in further studies. As shown in Figure [1](#F1){ref-type="fig"}, *miR-216a-5p/-3p* and *miR216b-5p/-3p* are located within the same chromosomal region (2q16.1).

###### Differentially expressed miRNAs in PDAC by RNA seqencing

  Downregulated miRNAs in PDAC                                                               
  ------------------------------ -------------- --------------------------- ------- -------- --------
  *hsa-miR-216a-5p*              MIMAT0000273   chr2:56216155-56216176      -3.22   0.0033   0.4602
  *hsa-miR-802*                  MIMAT0004185   chr21:37093030-37093052     -3.17   0.0001   0.0901
  *hsa-miR-3186-3p*              MIMAT0015068   chr17:79418142-79418162     -3.16   0.0072   0.5030
  *hsa-miR-217*                  MIMAT0000274   chr2:56210155-56210177      -3.13   0.0034   0.4602
  *hsa-miR-2114-5p*              MIMAT0011156   chrX:149396251-149396272    -3.08   0.0033   0.4602
  *hsa-miR-216b-5p*              MIMAT0004959   chr2:56227899-56227920      -2.77   0.0286   0.9691
  *hsa-miR-3186-5p*              MIMAT0015067   chr17:79418178-79418199     -2.70   0.0230   0.9200
  *hsa-miR-216b-3p*              MIMAT0026721   chr2:56227859-56227882      -2.58   0.0008   0.1722
  *hsa-miR-6510-3p*              MIMAT0025477   chr17:39673418-39673438     -2.57   0.0098   0.6010
  *hsa-miR-122-5p*               MIMAT0000421   chr18:56118320-56118341     -2.51   0.0207   0.8791
  *hsa-miR-412-3p*               MIMAT0002170   chr14:101531837-101531859   -2.42   0.0393   1.0000
  *hsa-miR-129-1-3p*             MIMAT0004548   chr7:127847973-127847994    -2.40   0.0011   0.2082
  *hsa-miR-216a-3p*              MIMAT0022844   chr2:56216116-56216137      -2.38   0.0214   0.8791
  *hsa-miR-135a-3p*              MIMAT0004595   chr3:52328248-52328269      -2.37   0.0008   0.1722
  *hsa-miR-148a-5p*              MIMAT0004549   chr7:25989580-25989601      -2.30   0.0009   0.1722
  *hsa-miR-891a-5p*              MIMAT0004902   chrX:145109359-145109380    -2.25   0.0053   0.5030
  *hsa-miR-190b*                 MIMAT0004929   chr1:154166189-154166209    -2.12   0.0003   0.1429
  *hsa-miR-148a-3p*              MIMAT0000243   chr7:25989542-25989563      -2.12   0.0001   0.0901
  *hsa-miR-211-5p*               MIMAT0000268   chr15:31357298-31357319     -2.10   0.0084   0.5545
  *hsa-miR-1224-5p*              MIMAT0005458   chr3:183959193-183959211    -2.05   0.0450   1.0000
  *hsa-miR-338-5p*               MIMAT0004701   chr17:79099723-79099744     -2.02   0.0002   0.0956
  *hsa-miR-129-2-3p*             MIMAT0004605   chr11:43603000-43603021     -2.01   0.0090   0.5650
  *hsa-miR-137*                  MIMAT0000429   chr1:98511647-98511669      -2.01   0.0874   1.0000

  ----------------------------------------------------------------------------------------------------
  **Upregulated miRNAs in PDAC**                                                              
  -------------------------------- -------------- --------------------------- ------ -------- --------
  *hsa-miR-6887-3p*                MIMAT0027675   chr19:35613648-35613668     4.13   0.0007   0.1722

  *hsa-miR-4713-5p*                MIMAT0019820   chr15:51534397-51534418     4.04   0.0039   0.4750

  *hsa-miR-615-5p*                 MIMAT0004804   chr12:54427751-54427772     3.61   0.0053   0.5030

  *hsa-miR-1248*                   MIMAT0005900   chr3:186504464-186504490    3.50   0.0002   0.0956

  *hsa-miR-490-3p*                 MIMAT0002806   chr7:136587989-136588010    3.47   0.0386   1.0000

  *hsa-miR-184*                    MIMAT0000454   chr15:79502182-79502203     3.46   0.0467   1.0000

  *hsa-miR-196a-5p*                MIMAT0000226   chr17:46709894-46709915\    3.24   0.0103   0.6146
                                                  chr12:54385546-54385567                     

  *hsa-miR-187-3p*                 MIMAT0000262   chr18:33484798-33484819     3.05   0.0195   0.8676

  *hsa-miR-6516-3p*                MIMAT0030418   chr17:75085551-75085572     3.03   0.0046   0.5030

  *hsa-miR-490-5p*                 MIMAT0004764   chr7:136587952-136587971    2.95   0.0457   1.0000

  *hsa-miR-3131*                   MIMAT0014996   chr2:219923447-219923469    2.94   0.0112   0.6428

  *hsa-miR-4697-3p*                MIMAT0019792   chr11:133768401-133768424   2.90   0.0070   0.5030

  *hsa-miR-615-3p*                 MIMAT0003283   chr12:54427794-54427815     2.86   0.0001   0.0901

  *hsa-miR-196b-5p*                MIMAT0001080   chr7:27209147-27209168      2.73   0.0009   0.1722

  *hsa-miR-187-5p*                 MIMAT0004561   chr18:33484834-33484855     2.70   0.0610   1.0000

  *hsa-miR-6886-3p*                MIMAT0027673   chr19:11224187-11224207     2.68   0.0247   0.9200

  *hsa-miR-650*                    MIMAT0003320   chr22:23165285-23165305     2.67   0.0138   0.7105

  *hsa-miR-492*                    MIMAT0002812   chr12:95228203-95228225     2.66   0.0257   0.9200

  *hsa-miR-6744-5p*                MIMAT0027389   chr11:1277840-1277858       2.65   0.0169   0.8201

  *hsa-miR-6805-5p*                MIMAT0027510   chr19:55899554-55899575     2.55   0.0603   1.0000

  *hsa-miR-935*                    MIMAT0004978   chr19:54485616-54485638     2.53   0.0059   0.5030

  *hsa-miR-4485*                   MIMAT0019019   chr11:10529824-10529843     2.53   0.0192   0.8676

  *hsa-miR-196a-3p*                MIMAT0004562   chr12:54385583-54385604     2.52   0.0627   1.0000

  *hsa-miR-1*                      MIMAT0000416   chr18:19408976-19408997\    2.48   0.0697   1.0000
                                                  chr20:61151558-61151579                     

  *hsa-miR-4768-5p*                MIMAT0019920   chrX:17444012-17444033      2.42   0.0567   1.0000

  *hsa-miR-6887-5p*                MIMAT0027674   chr19:35613609-35613631     2.39   0.0749   1.0000

  *hsa-miR-181b-3p*                MIMAT0022692   chr1:198828016-198828036    2.34   0.0827   1.0000

  *hsa-miR-4745-5p*                MIMAT0019878   chr19:804941-804963         2.32   0.0491   1.0000

  *hsa-miR-4724-5p*                MIMAT0019841   chr17:29861911-29861933     2.25   0.0950   1.0000

  *hsa-miR-6814-3p*                MIMAT0027529   chr21:43166932-43166953     2.15   0.0664   1.0000

  *hsa-miR-203b-3p*                MIMAT0019814   chr14:104583765-104583787   2.10   0.0518   1.0000

  *hsa-miR-143-5p*                 MIMAT0004599   chr5:148808507-148808528    2.09   0.0019   0.3270

  *hsa-miR-6850-5p*                MIMAT0027600   chr8:146017355-146017376    2.09   0.1212   1.0000

  *hsa-miR-549a*                   MIMAT0003333   chr15:81134334-81134354     2.06   0.1130   1.0000

  *hsa-miR-133a-3p*                MIMAT0000427   chr18:19405673-19405694\    2.06   0.0275   0.9691
                                                  chr20:61162177-61162198                     

  *hsa-miR-3661*                   MIMAT0018082   chr5:133561468-133561489    2.03   0.0800   1.0000

  *hsa-miR-4649-5p*                MIMAT0019711   chr7:44150450-44150473      2.02   0.0661   1.0000

  *hsa-miR-31-3p*                  MIMAT0004504   chr9:21512120-21512141      2.02   0.0195   0.8676

  *hsa-miR-6862-5p*                MIMAT0027625   chr16:28402346-28402367\    2.01   0.0770   1.0000
                                                  chr16:28735578-28735599                     
  ----------------------------------------------------------------------------------------------------

![Schematic representation of the human *miR-216* family in chromosomal location\
The *miR-216* family members and *miR-217* are located on human chromosome 2q16.1. Mature miRNAs, *miR-216a-5p* (guide strand) and *miR-216a-3p* (passenger strand) are derived from pre-*miR-216a*. Likewise pre-*miR-216a*, *miR-216b-5p* (guide strand) and *miR-216b-3p* (passenger strand) are derived from pre-*miR-216b*. Seed sequences of *miR-216a-5p* and *miR-216b-5p* are identical. In contrast, seed sequences of *miR-216a-3p* and *miR-216b-3p* are independent sequences.](oncotarget-08-70097-g001){#F1}

Expression levels of the *miR-216* family in PDAC specimens and cell lines {#s2_2}
--------------------------------------------------------------------------

We evaluated expression levels of the *miR-216 family* in PDAC tissues (n = 24), normal pancreatic tissues (n = 14) and two PDAC cell lines (PANC-1 and SW 1990). Patient clinicopathological features are summarized in Table [1](#T1){ref-type="table"}. The expression levels of *miR-216a-5p, miR-216a-3p, miR-216b-5p and miR-216b-3p* were significantly lower in tumour tissues than in normal pancreatic tissues (Figure [2](#F2){ref-type="fig"}). It was not recognized the significant relationships between any of the clinical parameters (i.e., TNM stage, metastasis or survival rate) and expression levels of any member of the *miR-216*-family (data not shown).

![Expression levels of *miR-216* family members\
Expression levels of *miR-216* family members in clinical specimens and PDAC cell lines were determined using qRT-PCR. Data were normalized to *RNU48* expression.](oncotarget-08-70097-g002){#F2}

To elucidate molecular mechanisms of low expression of the clustered miRNAs, *miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p* and *miR-216b-3p* in PDAC cells, PANC-1 and SW1990 cells were treated with the demethylating agent \[5-aza-2'-deoxycytidine (5-aza-dC)\]. Expression levels of all clustered miRNAs in PDAC cells were significantly elevated by 5-aza-dc treatment ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). These data suggested that DNA methylation might cause silencing of these clustered miRNAs in PDAC cells.

Expression of *miR-216* family members and the effects on cell growth, migration and invasion in PDAC cell lines {#s2_3}
----------------------------------------------------------------------------------------------------------------

The functional roles of the *miR-216*-family were performed by using restoration of mature miRNAs assays. Functional assays showed that proliferation, migration and invasion activities of cancer cells were significantly suppressed in *miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p* and *miR-216b-3p* transfectants compared with mock or miR-control transfectants (Figure [3](#F3){ref-type="fig"}). Present results suggested that the *miR-216* family could have anti-tumour functions in PDAC cells. Among the *miR-216* family, *miR-216b-3p* markedly inhibited PDAC cell aggressiveness (Figure [3](#F3){ref-type="fig"}).

![Effects of *miR-216a-5p, miR-216a-3p, miR-216b-5p* and *miR-216b-3p* transfection into PDAC cells\
**(A)** Cell growth was determined using XTT assays 72 h after transfection with 10 nM *miR-216* family members. \*, *P* \< 0.0001; \*\*, *P* \< 0.05. **(B)** Cell migration activity was determined using BD Falcon Cell Culture Inserts. \*, *P* \< 0.0001. **(C)** Cell invasion activity was determined using Matrigel invasion assays. \*, *P* \< 0.0001.](oncotarget-08-70097-g003){#F3}

We hypothesized that passenger strand of *miR-216-3p* may be incorporated into and function as part of the RISC structure. To check this hypothesis, we performed immunoprecipitation with antibody targeting Ago2, which plays a pivotal role in the RISC. After transfection with *miR-216-3p*, Ago2-bound miRNAs were isolated, and RT-qPCR was carried out to determine whether *miR-216-3p* bound to Ago2. Expression of *miR-216-3p* levels were significantly higher than those of mock and miRNA control transfected cells ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Moreover, expression levels of *miR-216a-5p*, *miR-216a-3p* and *miR-216b-5p* were same levels of mock and miRNA control transfectants ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

Identification of genes regulated by *miR-216b-3p* in PDAC cells {#s2_4}
----------------------------------------------------------------

To elucidate the molecular mechanisms and pathways regulated by anti-tumour *miR-216b-3p* in PDAC cells, we used a combination of gene expression and *in silico* analyses. Figure [4](#F4){ref-type="fig"} presents the strategy for narrowing down the target genes of *miR-216b-3p*. In gene expression analyses, 439 and 806 genes were downregulated (log~2~ ratio \<-1.0) in PANC-1 and SW 1990 *miR-216b-3p* transfectants, respectively, in comparison with control transfectants (GEO accession number, GSE82108). Next, we pared down the list of genes using the TargetscanHuman and GEO database (GEO accession number, GSE15471). We found that 20 genes were putatively targeted by *miR-216b-3p* in PANC-1 and SW 1990 *miR-216b-3p* transfectants.

![Flow chart illustrating the analytic strategy for *miR-216b-3p* target genes\
Strategy for identification of putative candidate genes regulated by *miR-216b-3p* in PDAC cells. Approach to identifying *miR-216b-3p* target genes by *in silico* analysis of genome-wide gene expression, TargetScan and GEO database analysis of *miR-216b-3p* transfectants and PDAC clinical specimens.](oncotarget-08-70097-g004){#F4}

Among these candidate genes, 6 genes (*PLAU*, *FOXQ1*, *PGM2L1*, *MBOAT2*, *PERP* and *UHMK1*) were significantly associated with poor prognosis of patients with PDAC (Table [4](#T4){ref-type="table"} and [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Past studies showed that aberrant expressed FOX-family of transcription factors were involved in several types of cancers, however, functional significance of *FOXQ1* in PDAC is still unclear.

###### Candidate target genes regulated by miR-216b-3p in PDAC

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez gene ID   Gene symbol   Description                                                          Microarray (Log~2~ ratio)\           Target site\   GEO   TCGA-OncoLncKaplan plot P-value   
                                                                                                      *miR-216b-3p*                        (Targetscan)                                           
  ---------------- ------------- -------------------------------------------------------------------- ---------------------------- ------- -------------- ----- --------------------------------- ----------
  5328             *PLAU*        plasminogen activator, urokinase                                     -1.03                        -1.10   -1.06          (+)   5.07                              0.0161

  59345            *GNB4*        guanine nucleotide binding protein (G protein), beta polypeptide 4   -1.76                        -2.27   2.01           (+)   4.57                              0.3330

  94234            *FOXQ1*       forkhead box Q1                                                      -1.50                        -1.52   -1.51          (+)   3.88                              0.0089

  9240             *PNMA1*       paraneoplastic Ma antigen 1                                          -1.24                        -1.69   -1.47          (+)   3.27                              0.9910

  283209           *PGM2L1*      phosphoglucomutase 2-like 1                                          -1.67                        -1.91   -1.79          (+)   3.23                              0.0477

  60481            *ELOVL5*      ELOVL fatty acid elongase 5                                          -1.50                        -2.77   -2.13          (+)   3.15                              0.4970

  129642           *MBOAT2*      membrane bound O-acyltransferase domain containing 2                 -1.20                        -1.40   -1.30          (+)   2.92                              0.0158

  5912             *RAP2B*       RAP2B, member of RAS oncogene family                                 -1.31                        -1.25   -1.28          (+)   2.74                              0.1040

  5738             *PTGFRN*      prostaglandin F2 receptor inhibitor                                  -1.57                        -2.00   -1.79          (+)   2.64                              0.4350

  493              *ATP2B4*      ATPase, Ca++ transporting, plasma membrane 4                         -1.45                        -2.27   -1.86          (+)   2.55                              0.0966

  54492            *NEURL1B*     neuralized E3 ubiquitin protein ligase 1B                            -1.32                        -1.95   -1.64          (+)   2.36                              0.0365

  64065            *PERP*        PERP, TP53 apoptosis effector                                        -1.78                        -1.98   -1.88          (+)   2.33                              \<0.0001

  160418           *TMTC3*       transmembrane and tetratricopeptide repeat containing 3              -1.85                        -2.24   -2.05          (+)   2.30                              0.9080

  55589            *BMP2K*       BMP2 inducible kinase                                                -1.04                        -1.54   -1.29          (+)   2.29                              0.5220

  3977             *LIFR*        leukemia inhibitory factor receptor alpha                            -1.96                        -2.09   -2.03          (+)   2.26                              0.0062\*

  10920            *COPS8*       COP9 signalosome subunit 8                                           -1.43                        -2.04   -1.73          (+)   2.20                              0.2740

  9637             *FEZ2*        fasciculation and elongation protein zeta 2 (zygin II)               -1.03                        -1.28   -1.15          (+)   2.18                              0.0974

  4286             *MITF*        microphthalmia-associated transcription factor                       -1.02                        -1.07   -1.05          (+)   2.17                              0.0963

  29967            *LRP12*       low density lipoprotein receptor-related protein 12                  -1.32                        -2.22   -1.77          (+)   2.09                              0.6200

  127933           *UHMK1*       U2AF homology motif (UHM) kinase 1                                   -1.20                        -1.79   -1.50          (+)   2.04                              0.0329
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Poor prognosis with a low expression

We determined that *FOXQ1* was upregulated in clinical PDAC samples using qRT-PCR (Figure [5A](#F5){ref-type="fig"}). Negative correlations between *miR-216b-3p* expression and *FOXQ1* mRNA expression were found using Spearman's rank test (*R* = -0.5160, *P* = 0.0006, Figure [5B](#F5){ref-type="fig"}). Kaplan--Meier survival curves constructed from PDAC patients in the TCGA dataset showed that patient groups with high expression of *FOXQ1* had significantly shorter overall survival (*P* = 0.0070; Figure [5D](#F5){ref-type="fig"}). The TCGA dataset was analysed by OncoLnc database (<http://www.oncolnc.org/>)\[[@R24]\].

![Expression of FOXQ1 (mRNA and protein) in PDAC and association of FOXQ1 with overall survival\
**(A)** Expression levels of *FOXQ1* in clinical specimens and PDAC cell lines were determined using qRT-PCR. Data were normalized to *GUSB* expression. **(B)** Correlation between *miR-216-3p* and *FOXQ1* expression. **(C)** Immunohistochemical staining of FOXQ1 in PDAC clinical specimens. Overexpression of FOXQ1 was observed in cancer lesions (original magnification ×400). In contrast, negative staining of FOXQ1 was observed in normal tissues. (IHC_13) Positively stained cancer lesion (T3N1M0). (IHC_18) Negatively stained cancer lesion (T3N0M0). (IHC_29) Negatively stained normal pancreas tissue. **(D)** TCGA-based large cohort study of high expression of FOXQ1 in 174 PDAC patients. **(E)** Kaplan-Meier patient survival curves for overall survival rates based on FOXQ1 expression in 35 patients with PDAC. P-values were calculated using the log-rank test.](oncotarget-08-70097-g005){#F5}

Expression of FOXQ1 in PDAC clinical specimens {#s2_5}
----------------------------------------------

We validated the expression of FOXQ1 in PDAC clinical specimens using immunohistochemistry. A total of 35 specimens were evaluated, and 12 samples were classified as having high expression of FOXQ1. Clinicopathological characteristics are summarized in Table [1](#T1){ref-type="table"}. Table [5](#T5){ref-type="table"} shows the correlation between FOXQ1 expression and various clinicopathological factors. High FOXQ1 expression was significantly associated with increased lymph node metastasis. Furthermore, patients with high FOXQ1 expression had significantly shorter OS than those with low FOXQ1 expression (*P =* 0.0007) (Figure [5E](#F5){ref-type="fig"}).

###### Correlation between the expression of FOXQ1 and clinicopathological factors in PDAC (n =35)

  Characteristic              FOXQ1   *P*   
  --------------------------- ------- ----- --------
  Age (y)^a^                                ^b^NS
   ≥ 60                       17      10    
   \< 60                      6       2     
  Gender (n)                                
   Male (20)                  13      7     NS
   Female (15)                10      5     
  Tumor size (n)                            
   \> 40 mm (5)               2       3     NS
   ≤ 40 mm (30)               21      9     
  Lymph node metastasis (n)                 
   No (11)                    10      1     0.0088
   Yes (24)                   11      13    
  Distant metastasis (n)                    
   No (35)                    23      12    NS
  TNM Stage (n)                             
   I / II (27)                18      9     NS
   III / IV (8)               5       3     
  Recurrence (n)                            
   No (8)                     6       2     NS
   Yes (27)                   17      10    

^a^Values are mean ± SD.

^b^NS, not significant.

Moreover, we categorized patients into two groups, with adjuvant chemotherapy or without adjuvant chemotherapy. Regardless of the treatment, patients with high FOXQ1 expression were associated with poor prognosis ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

We confirmed the expression of FOXQ1 in PDAC clinical specimens using immunohistochemistry. Expression of FOXQ1 was detected in in ductal carcinoma, not in normal ductal cells, acinar cells and islets cells ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

*FOXQ1* is a direct target of *miR-216b-3p* in PDAC cells {#s2_6}
---------------------------------------------------------

We performed qRT-PCR to validate *miR-216b-3p*-mediated reduction of *FOXQ1* mRNA expression in PDAC cell lines. Our studies demonstrated that *FOXQ1* mRNA was markedly reduced in *miR-216b-3p* transfectants compared to mock or miR-control transfectants (P \< 0.0001, Figure [6A](#F6){ref-type="fig"}). FOXQ1 protein expression was also repressed in the *miR-216b-3p* transfectants (Figure [6B](#F6){ref-type="fig"}).

![Direct regulation of FOXQ1 by *miR-216b-3p* in PDAC cells\
**(A)** *FOXQ1* mRNA expression was evaluated using qRT-PCR in PANC-1 and SW 1990 cells 72 h after transfection with *miR-216b-3p*. *GUSB* was used as an internal control. \*, *P* \< 0.0001. **(B)** FOXQ1 protein expression was evaluated by Western blotting in PANC-1 and SW 1990 cells 72 to 96 h after transfection with *miR-216b-3p*. GAPDH was used as a loading control. **(C)** *miR-216b-3p* binding sites in the 3'-UTR of *FOXQ1* mRNA. Dual luciferase reporter assays using vectors encoding putative *miR-216b-3p* target sites of the *FOXQ1* 3'-UTR (positions 463-468 and 720-727) for both wild-type and deleted regions. Data were normalized by expressing ratios of *Renilla*/firefly luciferase activities. \*, *P* \< 0.0001.](oncotarget-08-70097-g006){#F6}

Target prediction databases indicated the presence of 2 putative target sites in the 3\'-UTR of *FOXQ1* (Figure [6C](#F6){ref-type="fig"}). To determine whether *FOXQ1* mRNA had a functional target site, we performed luciferase reporter assays. Compared with the miR-control, luminescence intensity was significantly reduced by transfection with *miR-216b-3p* at its target site, position 720-727 in the 3'-UTR of *FOXQ1* (Figure [6C](#F6){ref-type="fig"}).

Effects of silencing *FOXQ1* on PDAC cell lines {#s2_7}
-----------------------------------------------

To investigate the oncogenic functions of *FOXQ1* in PDAC cells, we carried out knockdown assays by using si-*FOXQ1*. First, we evaluated the knockdown efficiency achieved by si-*FOXQ1* transfection of PDAC cell lines. We used 2 types of si-*FOXQ1* (si-*FOXQ1-1* and si-*FOXQ1-2*) in this study. Both siRNAs effectively downregulated *FOXQ1* expression in bothcell lines (Figure [7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Functional assays showed that si-*FOXQ1* transfection significantly reduced cell proliferation, migration and invasion compared with mock- or siRNA-control-transfected cells (Figure [7C-7E](#F7){ref-type="fig"}).

![Effects of FOXQ1 silencing on PDAC cell lines\
**(A)** *FOXQ1* mRNA expression was evaluated using qRT-PCR analysis of PANC-1 and SW 1990 cells 72 h after transfection with *si-FOXQ1*-1 or *si-FOXQ1*-2. *GUSB* was used as an internal control. **(B)** FOXQ1 protein expression was evaluated using Western blotting analysis of PANC-1 and SW 1990 cells 72 to 96 h after transfection with *miR-216b-3p*. GAPDH was used as a loading control. **(C)** Cell proliferation was determined using XTT assays 72 h after transfection with 10 nM *si-FOXQ1*-1 or *si-FOXQ1*-2. \*, *P* \< 0.0001; \*\*, *P* \< 0.05. **(D)** Cell migration activity was determined using BD Falcon Cell Culture Inserts. \*, *P* \< 0.0001. **(E)** Cell invasion activity was determined using Matrigel invasion assays. \*, *P* \< 0.0001.](oncotarget-08-70097-g007){#F7}

In contrast to loss-of-function assays, overexpression of *FOXQ1* enhanced cancer cell migration and invasion in PANC-1 cells ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}).

Investigation of *FOXQ1*-mediated downstream genes in PDAC cells {#s2_8}
----------------------------------------------------------------

Genome-wide gene expression (GEO accession number, GSE77790) and *in silico* analyses were performed to investigate the downstream genes mediated by *FOXQ1* in a PDAC cell line (PANC-1) transfected with si-*FOXQ1*. A total of 18,277 genes were commonly downregulated (log~2~ ratio \< 0). Further GEO analyses showed that 1,003 genes upregulated expression (log~2~ ratio \> 1.0) in GEO accession number GSE15471. Next, we assigned genes to KEGG pathways using the GENECODIS program and identified 261 pathways. In the top 3 pathways, 41 genes were significantly enriched ([Supplementary Tables 3A and 3B](#SD1){ref-type="supplementary-material"}).

TCGA database analyses demonstrated that high expression of 13 genes were significantly associated with poor survival in patients with PDAC ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

miRNA fine-tunes the expression control of protein coding/noncoding RNAs by repressing translation or cleaving RNA transcripts. Dysregulated miRNAs can disrupt tightly controlled RNA networks and thereby enhance the aggressiveness of cancer cells. Identification of dysregulated miRNAs and their targeted genes can improve our understanding of the molecular pathogenesis of human cancers. In that regard, we have identified novel RNA networks in several cancers \[[@R13]--[@R15]\].

In the present study, we newly constructed a miRNA expression signature of PDAC by RNA sequencing methods. Several miRNA signatures of PDAC were reported in which formalin-fixed paraffin-embedded tissue or fine-needle aspiration biopsies specimens were used for PCR or microarray-based applications \[[@R25]--[@R27]\]. Recently, we summarized dysregulated miRNAs in PDAC using information in public databases \[[@R12]\]. Downregulation of *miR-217*, *miR-141*, *miR-148a* and *miR-375* in PDAC tissues was commonly observed in PDAC tissues \[[@R12]\]. More recently, we demonstrated the anti-tumour roles of *miR-375* through its targeting of *ZFP36L2* in PDAC cells \[[@R28]\]. Our present signature included several anti-tumour miRNAs that had been previously identified in PDAC, suggesting that our RNA-based signature was effective for identification of novel oncogenes and anti-tumour miRNAs in PDAC cells. These data may provide a benchmark for future studies of PDAC.

Our signature revealed that novel miRNAs were aberrantly expressed in PDAC cells. Among them, we focused on 4 clustered miRNAs, *miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p* and *miR-216b-3p* located on human chromosome 2p16.1. Here, we showed that the clustered *miR-216* family has anti-tumour activity in PDAC. Those results suggest that the *miR-216* family is important in PDAC oncogenesis. Past studies showed that guide strands of *miR-216a-5p* and *miR-216b-5p* acted as anti-tumour miRNAs in several cancers \[[@R29], [@R30]\]. On the other hand, the functional significance of passenger strands *miR-216a-3p* and *miR-216b-3p* has not been adequately analysed.

In miRNA biogenesis, the RNA guide strand from the duplex is recruited to the RNA-induced silencing complex (RISC) to target messenger RNAs, whereas the passenger strand is degraded and no functional activity \[[@R31], [@R32]\]. Nevertheless, our present data showed that passenger strands *miR-216a-3p* and *miR-216b-3p* have anti-tumour functions in PDAC cells. Recently, we demonstrated that both strands of *pre-miR-145* (*miR-145-5p*, guide strand, and *miR-145-3p*, passenger strand) were incorporated into RISC and function anti-tumour miRNAs by targeting several oncogenes in bladder and lung cancer cells \[[@R21], [@R22]\]. The involvement of passenger strand miRNAs in the regulation of cellular processes is a novel concept in RNA research.

The *Kras*^G12D^ oncogene is a key oncogenic mutation that is associated with development of PDAC \[[@R33], [@R34]\]. A recent study evaluated miRNA expression in the *Kras*^G12D^ transgenic mouse model of PDAC \[[@R35]\]. In that study, 3 miRNAs (*miR-216a*, *miR-216b*, and *miR-217*) were reduced in expression in the *Kras*^G12D^ pancreas. Other study showed that significantly downregulation of *miR-216a* and *miR-217* was detected in Kras^G12d^;Pdx1-Cre mouse at 25 weeks \[[@R36]\]. Due to the lack of human clinical specimens from early stages of PDAC, the investigation is important to analyze expression patterns of miRNAs in early stages of PDAC by using mouse model. The molecular mechanisms of downregulation of these clustered miRNAs are still obscure.

To better understand and identify the anti-tumour targets of *miR-216b-3p* in PDAC cells, we have applied *in silico* database and genome-wide gene expression analyses. In this study, *FOXQ1* (a member of the forkhead transcription factor family) was identified as a direct target of *miR-216b-3p* regulation in PDAC cells. Moreover, our functional studies revealed that expression of *FOXQ1* promoted cancer cell aggressiveness, and overexpression of *FOXQ1* was involved in PDAC pathogenesis. The FOX-family consists of a large number of transcription factors that have been categorized in 19 subfamilies, FOXA-FOXS \[[@R37], [@R38]\]. FOX transcription factors play pivotal roles in regulating the expression of genes involved in several biological processes \[[@R37], [@R38]\]. Numerous studies have demonstrated that *FOXQ1* (as well as other FOX-family member) is associated with the progression, metastasis and drug resistance of human cancers \[[@R39]\].

The epithelial-mesenchymal transition (EMT) is pivotal in cancer cell invasion, metastasis and chemoresistance \[[@R40], [@R41]\]. Many EMT-promoting transcription factors have been implicated in these events in cancer cells \[[@R40], [@R41]\]. In lung cancer cells, elimination of *FOXQ1* affected the re-expression of epithelial markers and decreases mesenchymal markers *in vitro* and *in vivo*\[[@R42]\]. Similar studies reported that upregulation of *FOXQ1* triggered EMT and contributed to metastasis and chemoresistance in several cancers \[[@R43]--[@R45]\]. The existence of cancer stem cells (CSCs) is an important concept in cancer cell aggressiveness, metastasis and chemoresistance \[[@R46]\]. In PDAC, CSCs were isolated based on expression of CD44, CD133 and EpCAM. Overexpression of FOXQ1 was detected in CSCs and CSCs behaver have more aggressiveness for cell growth, compared with parental MiaPaCa-2 cells \[[@R47]\].

A large number of cohort analyses of the TCGA dataset showed that high expression of *FOXQ1* predicted shortened survival of patients with PDAC. Likewise, there are many reports that expression of *FOXQ1* indicates poor prognosis \[[@R44], [@R45], [@R48]\]. In this study, we identified "ECM-receptor interaction", "regulation of actin cytoskeleton" and "focal adhesion pathways" as *FOXQ1*-mediated downstream pathways in PDAC cells. Interestingly, among 41 downstream genes of *FOXQ1*, 13 genes were associated with poor prognosis of patients with PDAC by TCGA analyses. These findings suggest that expression of *FOXQ1* and *FOXQ1*-mediated pathways contribute significantly to PDAC aggressiveness.

Our miRNA signature showed that *miR-217* was also markedly reduced in PDAC tissues. This miRNA is located in the same genomic region as the *miR-216* cluster. Our data showed that ectopic expression of *miR-217* significantly inhibited cancer cell aggressiveness in PDAC cells by targeting focal adhesion pathways (data not shown). Past studies pointed to the anti-tumour function of *miR-217* in several cancers, including the targeting of the *KRAS* oncogene in PDAC \[[@R49]\].

In conclusion, downregulation of 4 clustered miRNAs (*miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p* and *miR-216b-3p*) was detected by RNA sequencing-based miRNA signature analysis. The tumour-suppressor functions of these miRNAs were shown in PDAC cells. The expression of *FOXQ1* was directly regulated by *miR-216b-3p* and its overexpression was involved in PDAC pathogenesis. Identification of novel cancer networks mediated by aberrantly expressed miRNAs and tumour-suppressor miRNAs may improve our understanding of PDAC molecular pathogenesis. Our newly created RNA sequencing-based miRNA signature provides a basis for further PDAC research.

MATERIALS AND METHODS {#s4}
=====================

Clinical specimens and cell lines {#s4_1}
---------------------------------

We used fresh (n = 24) and preserved (formalin-fixed, paraffin-embedded blocks) (n = 35) specimens for the current study. Tissues were obtained from PDAC patients who underwent surgery at Kagoshima University Hospital between 1991 and 2014. Normal pancreatic tissue specimens (n = 14) were collected from noncancerous tumour-adjacent tissue. Each surgical specimen was histologically classified according to the TNM classification system \[[@R50]\]. All patients in this study provided informed consent and the study protocol was approved by the Institutional Review Board of Kagoshima University. Patient information and clinicopathological features are shown in Table [1](#T1){ref-type="table"}.

Two human PDAC cell lines were used in this study. PANC-1 cells were obtained from the RIKEN Cell Bank (Tsukuba, Ibaraki, Japan) and SW 1990 cells were obtained from the ATCC (Manassas, Virginia, USA).

Construction of the miRNA expression signature in PDAC {#s4_2}
------------------------------------------------------

Total RNAs from 7 PDAC tissues and 4 normal pancreatic tissues were subjected to RNA sequencing. The construction procedure of miRNA signature included the following steps: small RNA isolation, cDNA library preparation and sequencing as described previously \[[@R14]\]

Quantitative real-time RT-PCR {#s4_3}
-----------------------------

Quantification of miRNA was performed using qRT-PCR as previously described \[[@R20], [@R28], [@R51], [@R52]\]. We used the following probes and primers: *miR-216a-5p* (product ID: 2220; Thermo Fisher Scientific, Waltham, MA, USA), *miR-216a-3p* (product ID: 475580_mat), *miR-216b-5p* (product ID: 2326), *miR-216b-3p* (product ID: 467177_mat), *PLAU* (product ID: Hs01547054_m1), *GNB4* (product ID: Hs00222147_m1) and *FOXQ1* (product ID: Hs00536425_s1. Human *GUSB* (product ID: Hs99999908_m1) and *RNU48* (product ID: 001006) were used as internal controls.

Transfection of miRNA mimic and small interfering RNA (siRNA) into PDAC cell lines {#s4_4}
----------------------------------------------------------------------------------

PDAC cell lines were transfected with a miRNA mimic for gain-of-function experiments and siRNA for loss-of-function experiments. Pre-miR^™^ miRNA precursors for *miR-216a-5p* (product ID: PM10545; Thermo Fisher Scientific), *miR-216a-3p* (product ID: PM24316), *miR-216b-5p* (product ID: PM12302), *miR-216b-3p* (product ID: PM28358), negative control miRNA (product ID: AM 17111), two *FOXQ1* siRNAs (product IDs: s41290 and s41291) and control siRNA (product ID: D-001810-10) were purchased from Thermo Fisher Scientific. The transfection efficiencies of miRNA in PANC-1 and SW 1990 cells were calculated as described in previous studies \[[@R20], [@R28], [@R51], [@R52]\].

Cell proliferation, migration and invasion assays {#s4_5}
-------------------------------------------------

Cell proliferation, migration and invasion assays were described previously \[[@R20], [@R28], [@R51], [@R52]\].

Western blot analyses {#s4_6}
---------------------

Mouse anti-FOXQ1 antibodies (product ID: sc-166266; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were diluted 1:500 for immunoblotting. Anti-GAPDH antibodies at a 1:1000 dilution (product ID: 010-25521; Wako, Osaka, Japan) were used as an internal loading control.

Immunohistochemistry {#s4_7}
--------------------

Tissue sections were incubated overnight at 4°C with anti-FOXQ1 antibodies diluted 1:300 (product ID: ab51340; Abcam, Cambridge, UK). Cytoplasmic staining of FOXQ1 in at least 1% of cancer cells was classified as high. If no cancer cells were stained, specimens were classified as negative for FOXQ1 staining. The expression of FOXQ1 was evaluated in 10 fields of 100 cells each using high-power microscopy (400×).

Genome-wide gene expression and *in silico* analyses {#s4_8}
----------------------------------------------------

To identify *miR-216b-3p* target genes, a combination of genome-wide gene expression and *in silico* analyses was conducted as described previously \[[@R20], [@R28], [@R51], [@R52]\]. The microarray data were deposited into the Gene Omnibus database (GEO) repository under the accession number GSE82108. Next, we selected putative miRNA target genes using the TargetScanHuman (August, 2015 release, <http://www.targetscan.org/vert_70>) database.

Construction of plasmid vectors and dual luciferase reporter assays {#s4_9}
-------------------------------------------------------------------

Wild-type sequences of the 3^׳^-UTR of *FOXQ1* containing the 2 *miR-216b-3p* target sites (positions 463-468 or 720-727) sequences or lacking a *miR-216b-3p* target site were inserted in the psiCHECK-2 vector (product ID: C8021; Promega, Madison, WI, USA). The procedure was described previously \[[@R20], [@R28], [@R51], [@R52]\].

Identification of downstream targets regulated by *FOXQ1* in PDAC {#s4_10}
-----------------------------------------------------------------

Gene expression analyses of si-*FOXQ1*-transfected PANC-1 cells revealed molecular pathways and targets regulated by *FOXQ1* in PDAC cells. This method was described in detail in previous studies \[[@R15], [@R20]\]. Microarray results were deposited in the GEO database (accession number GSE77790).

Statistical analysis {#s4_11}
--------------------

Relationships between expression values in 2 conditions or variables were analysed using the Mann-Whitney U test, and relationships between expression values in 3 conditions or variables were analysed using Bonferroni-adjusted Mann-Whitney U test. The correlation between the expression levels of *miR-216b-3p* and *FOXQ1* was evaluated using Spearman\'s rank test. Associations between different categories were assessed using Fisher's exact test and the chi-squared test. Overall survival (OS) after surgery was gauged using Kaplan--Meier curves. Patients were divided into two groups based on *FOXQ1* expression, and differences in survival were estimated using the log-rank test. We used Expert StatView software (version 5.0 SAS Institute Inc., Cary, NC, USA) for these analyses.
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